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April 2, 2013:1461–8went catheter ablation. The rationale for such a study is based on
accumulative evidence indicating that inflammatory pathways are
of significance in AF. After both catheter ablation and cardiac
surgery, leukocytosis and proinflammatory cytokines have been
directly related to the incidence of post-procedural AF (2,3). As
the cytokines increase, the risk of AF concomitantly increases.
Therefore, colchicine, a potent anti-inflammatory agent, may have
a relevant role in preventing inflammatory-facilitated AF after
catheter ablation.
The study shows an interesting correlation between the bio-
marker levels and the rate of AF recurrences. However, inflam-
matory biomarkers also have been correlated with the amount of
energy delivered (2). Therefore, the extensive ablation strategy
performed in the present study (50% of patients underwent
complex atrial fractionated electrogram ablation) may have affected
the proinflammatory state after ablation, which may have overes-
timated the role of colchicine in this series compared with
less-extensive AF ablation procedures. Furthermore, the role of
complex atrial fractionated electrogram ablation in paroxysmal AF
is at least controversial, which makes the results less relevant to
conventional pulmonary vein isolation in patients with paroxysmal
AF and mild cardiac disease (4). In addition, although some
evidence suggests that inflammation might be a causative agent for
AF (5), a substantial body of evidence supports that AF and
inflammatory pathways have a bidirectional relationship (6). Thus,
other substrates such as persistent AF, with both higher baseline
levels of biomarkers and the need for more extensive atrial ablation
(4,7), might benefit from using colchicine to prevent AF recur-
rences after the procedure.
The short-term follow-up precludes extrapolating the results to
longer periods, despite the short-term concomitant proinflammatory
state after ablation. As reported in the 5A Study at the 6-month
follow-up (8), short-term use of antiarrhythmic drugs after paroxys-
mal AF ablation reduced early recurrence of atrial arrhythmias.
However, early use of antiarrhythmic drugs did not prevent recur-
rences at 6 months. Therefore, similar results might be observed after
6 months of colchicine. In addition, a significantly higher number of
patients receiving colchicine reported diarrhea compared with patients
receiving placebo, and up to 12.3% discontinued the drug. Colchicine
may have deteriorated the quality of life of patients in the colchicine
group, despite the potential benefit of reducing the arrhythmia
burden. Thus, it seems reasonable to predict that longer periods under
colchicine will show similar rates of secondary effects, which makes it
necessary to include a disease-specific quality of life questionnaire in
future trials assessing the role of colchicine over longer periods of
follow-up.
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Reply
We thank Dr. Filgueiras-Rama and colleagues for their interest in
our work. We agree that 3 months of follow-up are not enough to
demonstrate the clinical efficacy of an intervention against atrial
fibrillation (AF) recurrence. This is exactly why the aim of our
paper, as clearly stated in the introduction of our published paper
(1), was not to demonstrate long-term clinical efficacy. The goal
was rather to prove the principle that an anti-inflammatory
treatment, which can be administered safely for a relatively
prolonged period of time (and only colchicine has these charac-
teristics among existing anti-inflammatory treatment options) can
lead to a reduction in the rate of AF recurrence within the time
limits during which inflammatory processes are perceived to play a
role in post-ablation AF recurrence (i.e., a few weeks to 2 to 3
months). To study long-term clinical efficacy, we have an extended
protocol underway and 1-year results will be published in due time.
These results also will include quality-of-life assessment measures.
We hope that this will address the authors’ concerns regarding the
effect of colchicine treatment on quality of life. However, it should
be noted that, according to our experience, most patients are more
frustrated and disappointed by a recurrence of their arrhythmia (by
which they were, after all, troubled enough to consent to undergo
an interventional procedure) than by mostly mild and easily
manageable gastrointestinal side effects.
R1466 Correspondence JACC Vol. 61, No. 13, 2013
April 2, 2013:1461–8The claim that patients receiving more aggressive ablation
protocols (including ablation of complex fractionated electro-
grams) would be more likely to benefit from colchicine treatment
is obviously an issue to be determined by future research. However,
our data do not show an interaction between the ablation of
complex fractionated electrograms and the reduction of AF recur-
rence by colchicine. On a more general note, our findings seem to
be independently corroborated by a similar smaller study from
Japan, presented in the 2012 American Heart Association Scien-
tific Sessions by Egami et al. (2), showing that a 2-week course of
colchicine resulted in less AF recurrences after ablation for
paroxysmal AF. As for the conjecture of Filgueiras-Rama et al.
that “other substrates such as persistent AF, [. . .] might benefit
from using colchicine to prevent AF recurrences after the proce-
dure,” it might be true, but we are not aware of any existing
evidence to support it. From a pathophysiological point of view,
one would actually expect anti-inflammatory treatment to be less
effective in persistent or permanent AF, where structural substrate
factors are known to play a prominent part in AF recurrence and
perpetuation, than in paroxysmal AF, where substrate alterations
are expected to be less marked.
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American College of Cardiology
Foundation Recommendations
Assume Incorrectly That Cardiac
Troponins T and I Are Equally
Cardiac Specific
The American College of Cardiology Foundation (ACCF), in
collaboration with the American Heart Association and other
organizations, has produced recommendations designed to helpclinicians with the practical interpretation of elevated cardiac
troponin (1). The document can be regarded as a companion to the
also recently published “Third Universal Definition of Myocardial
Infarction” (2). By necessity, the recommendations in the 2
documents are harmonized. This unfortunately also means that a
fundamental error in one has been repeated in the other. Both
documents refer to cardiac troponin (cTn) as one entity and make
no distinction between cTnT and cTnI. Elevation of either marker
in the circulation is viewed as virtually diagnostic of myocardial
necrosis. There are important biological and analytical differences
between the 2 cardiac troponins that directly affect diagnosis and
decision making.
The first point to make is that cTnT, unlike cTnI, is not cardiac
specific. During fetal development, cTnT exists in both cardiac
and skeletal muscles (3,4). After birth, it gradually disappears from
skeletal muscle, such that healthy skeletal muscle in adults (and
children) do not contain either cTnT or cTnI. However, when
skeletal muscle is injured, it repairs itself by regeneration, a process
that recapitulates embryonic myogenesis and causes re-expression
of fetal proteins, including cTnT. Thus, diseased skeletal muscle
contains cTnT in addition to skeletal troponins T and I (5,6).
The second issue regards the claim that the Roche (Mannheim,
Germany) cTnT analyzer is cardiac specific despite the analyte not
being organ specific. It was previously thought that the 2 antibod-
ies of the assay would apparently not be able to detect cTnT in
diseased skeletal muscle, based on a study of patients with
end-stage renal disease (7). It was assumed that the same would
hold true for patients with skeletal muscle diseases in general,
although no similar studies were performed in this group of
patients. The validation study of the newly introduced high-
sensitivity cTnT assay (8) simply showed that its 2 antibodies did
not cross react with skeletal troponins, which is insufficient for
claiming cardiac specificity. The central question of whether the
assay cross reacts with cTnT or its isoforms in diseased skeletal
muscle was not addressed.
There are clinical and laboratory evidence to show the Roche
assay cannot distinguish between cTnT from cardiac muscle and
that from diseased skeletal muscle. Whereas injury to myocardium
causes the simultaneous release of both cTnI and cTnT into the
circulation, chronic injury to skeletal muscle causes the release of
cTnT but not cTnI, as predicted by their different biological
expressions (9–11). The characteristic biochemical profile of pa-
tients with skeletal myopathies consists of persistent elevation of
creatine kinase, creatine kinase myocardial band, and cTnT but
normal cTnI, and N-terminal pro–B-type natriuretic peptide (12).
Western blot studies on skeletal muscle biopsies have confirmed
that the antibodies used in the Roche’s standard and high-
sensitivity assays are not cardiac specific, but are also immunore-
active against cTnT (or its isoforms) found in diseased skeletal
muscle (13).
Elevation of cTnT in the blood can have dual clinical
significance—myocardial damage or skeletal muscle repair. The
ACCF and other organizations will need to amend their recom-
mendations to take account of the fundamental differences be-
tween cTnI and cTnT.
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